Option chain shows key data for Instadose Pharma's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Instadose Pharma.

Instadose Pharma (OTC:INSD) Stock, Option Chain

Instadose Pharma Corp is seeking to create a distribution platform for medicinal cannabis and cannabinoid oil. The company endeavors to utilize the Global Distribution Platform to open the commercial gateway to a new wholesale marketplace along with providing pharmaceutical industry companies with large sustainable consistent diverse and low-cost supplies of high-quality medicinal cannabis and cannabinoid oil for use in bulk as an active pharmaceutical ingredient.

Cannabis

News

Penny Stocks

Entrepreneurship

Movers & Shakers

Small Cap

Markets

General

CCHWF

INSD

LOWLF

MCMJ

CSE:CCHW

CSE:LOWL

Columbia Care Welcomes Derek Watson As CFO

Columbia Care Inc. (NEO: CCHW) (CSE: CCHW) (OTCQX: CCHWF) (FSE:3LP) announced on Tuesday that it has tapped Derek Watson to oversee its finance department.

Cannabis Movers &amp; Shakers: Columbia Care, Lowell Farms, Leafly, Instadose, Michael J. Fox Foundation

Instadose Pharma Corp (OTCPK: INSD) reported Wednesday that it recently delivered a record-breaking shipment, 2.124 metric tons, of high-quality medical cannabis flower from Johannesburg, South Africa to Skopje, North Macedonia, destined for licenced pharmaceutical clients in the European Union

Instadose Pharma Touts Having Completed Largest International Cannabis Delivery: Over 2 Metric Tons

Broad U.S. Equity ETFs

Specialty ETFs

Intraday Update

ETFs

KNOW

QQQE

VLAT

VSPR

Direxion to Shutter 3 ETFs

INSTADOSE PHARMA CORP by Instadose Pharma Corp.

Instadose Pharma Corp

<h3>Columbia Care Welcomes Derek Watson As CFO</h3>
Columbia Care Inc. (NEO: CCHW) (CSE: CCHW) (OTCQX: <a class="ticker" href="https://www.benzinga.com/stock/cchwf#OTCQX">CCHWF</a>) (FSE:3LP) announced on Tuesday that it has tapped Derek Watson to oversee its finance department.
Watson has over three decades of finance and leadership experience and vast knowledge in strategy, investor relations, information technology, tax, treasury, accounting, financial planning and analysis, operational improvement&nbsp;and risk management.
&ldquo;We have found the right match in Derek and are thrilled to welcome him on board next week,&rdquo; Nicholas Vita, CEO of Columbia Care&nbsp;said. &ldquo;His decades of experience will serve him well, and his hands-on dedication to collaboration and innovation are exactly what we need in a CFO to take us into the next phase of our company.&rdquo;
<h3>Lowell Farms Welcomes Jeff Monat To Board Of Directors</h3>
Cannabis company Lowell Farms Inc. (CSE: LOWL) (OTCQX: <a class="ticker" href="https://www.benzinga.com/stock/lowlf#OTCQX">LOWLF</a>) said Friday that it has tapped veteran finance executive and cannabis investor Jeff Monat to serve on its board of directors.
Monat is a senior partner at Merida Capital Holdings, a private equity firm targeting fundamental growth drivers underpinning the rapid development of the cannabis industry. His appointment comes as Kevin McGrath departs the Lowell Farms board of directors.
In addition to being an investor in cannabis companies for nearly a decade, he serves on the board of directors at Merida Merger Corporation&nbsp;and as chairman of the board of Steep Hill, Incorporated. He previously worked in analyst roles for Seven Locks Capital, Rockbay Capital, and Goldman Sachs, where he advised clients on M&amp;A transactions, financial valuation&nbsp;and corporate governance issues.
&ldquo;With Jeff, we have immediately expanded the knowledge, expertise, and perspective of our board,&rdquo; said George Allen, chairman of the company&rsquo;s board. &ldquo;Not only does he bring unrivaled experience, but also a fundamental understanding of the economics of this massive and still-evolving industry.&rdquo;
<h3>Leafly Bolsters Leadership Team Ahead Of Going Public Via Deal With Merida</h3>
Cannabis information platform Leafly Holdings&nbsp;recently revealed that Jeff Oberlander will&nbsp;join its team as senior vice president of engineering.
At his new position Oberlander will lead the technical vision for Leafly&rsquo;s software development and product engineering teams. He will play a critical role in ensuring that the Leafly platform delivers world-class consumer experiences, cutting-edge tools for retail and brand partners&nbsp;and advocates for federal legalization and social equity within the cannabis industry.
Oberlander brings over three decades of experience in the Seattle software industry to the Seattle-based company, including leading and growing product engineering teams at scale.
His career spans roles at large enterprises like Boeing and Washington Mutual and startups, including Pipeline and Navigating Cancer. He also spent nearly a decade at Getty Images.
&ldquo;Jeff&rsquo;s deep expertise growing and managing product engineering will be essential as we continue to develop industry-leading tools on Leafly.com,&rdquo; Yoko Miyashita, the company&rsquo;s CEO&nbsp;said. &ldquo;His passion for delivering high-quality products will enable Leafly to grow at scale while ensuring we&rsquo;re providing the best possible experience for our retail and brand partners, as well as consumers.&rdquo;
In the meantime, Oberlander&rsquo;s appointment follows several key leadership hires ahead of the company&rsquo;s intent to combine with Merida Merger Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mcmj#NASDAQ">MCMJ</a>).
<h3>Instadose Pharma&nbsp;US Announces Management Shakeups</h3>
Nevada-based Instadose Pharma Corp (OTCPK: INSD) announced on Friday that they have accepted the planned resignation of Grant F. Sanders as chairman and CEO of Instadose US and as chairman of its wholly-owned Canadian subsidiary.
Following his resignation, he will not hold any officer or director positions at Instadose US or Instadose Canada.
Sanders had led Instadose Canada through its transition to a publicly-traded US company. On Dec.31, 2021, the exchange of shares from Instadose Canada to Instadose US was completed. The company also <a href="https://www.benzinga.com/markets/cannabis/22/01/24911192/instadose-pharma-touts-having-completed-largest-international-cannabis-delivery-over-2-metric-to">delivered</a> a record-breaking shipment, 2.124 metric tons, of high-quality medical cannabis flower from Johannesburg, South Africa&nbsp;to Skopje, North Macedonia where it was destined for licensed pharmaceutical clients in the European Union.
During a 30-day transition period, Sanders will continue to support Instadose US and its wholly-owned subsidiary with his in-depth knowledge of this global cannabis distribution platform.
In addition, Ed Borkowski has decided not to accept the position of CEO of Instadose Canada and instead agreed to assume the position as vice chairman of Instadose Canada.
<h3>Michael J. Fox Foundation Policy SVP To Join Board Of Directors Of Council For Federal Cannabis Regulation</h3>
On Thursday, the Council for Federal Cannabis Regulation (CFCR) announced that Ted Thompson, JD, senior vice president for public policy at The Michael J. Fox Foundation for Parkinson&rsquo;s Research (MJFF), will join CFCR leadership as a member of their board of directors.
Thompson brings over 25 years of experience in public policy, government relations, and nonprofit management.
&ldquo;People and families living with Parkinson&rsquo;s disease have the right to demand public and private support for research into every potential treatment, including medical cannabis, that could safely and effectively help manage the disabling motor and non-motor symptoms of PD,&rdquo; Thompson said. &ldquo;As a member of the CFCR Board, I&rsquo;ll work to help create momentum on legislative and other regulatory fronts for improved access to cannabis in Parkinson&rsquo;s research and care.&rdquo;
Photo: Courtesy of <a href="https://unsplash.com/@daconja?utm_source=unsplash&amp;utm_medium=referral&amp;utm_content=creditCopyText">David Gabrić</a> on <a href="https://unsplash.com/s/photos/cannabis?utm_source=unsplash&amp;utm_medium=referral&amp;utm_content=creditCopyText">Unsplash</a>

Cannabis Movers & Shakers: Columbia Care, Lowell Farms, Leafly, Instadose, Michael J. Fox Foundation

Instadose Pharma Corp (OTCPK: INSD)&nbsp;reported Wednesday that it recently&nbsp;delivered&nbsp;a record-breaking shipment,&nbsp;2.124 metric tons, of&nbsp;high-quality medical cannabis flower&nbsp;from Johannesburg, South Africa to Skopje, North Macedonia,&nbsp;destined for licenced pharmaceutical clients in the European Union.&nbsp;
&quot;This is a historic shipment and represents just the beginning of Instadose Pharma&#39;s potential.&nbsp; This delivery validates our business model and Instadose Pharma Corp as global leader in this industry,&rdquo; Grant F. Sanders, Instadose&nbsp;founder and chairman stated. &ldquo;This has always been my vision and I am very excited about what this delivery means and what is on the horizon.&quot;
The&nbsp;Virginia-based Instadose Pharma noted that this successful delivery establishes the company as a world leader in the international supply of high quality outdoor grown medicinal cannabis and agricultural pharmaceutical ingredients.
<h3>About Instadose </h3>
Instadose specializes in top grade medicinal cannabis flower that contains high levels of THC. Its global distribution platform spans five continents to date, including Africa, Europe, Asia, South America&nbsp;and North America. Within each continent, the company is establishing operational subsidiaries and joint venture partnerships to secure access to government-issued licenses and permits in countries including the Democratic Republic of the Congo, North Macedonia, Portugal, India, Colombia, Mexico&nbsp;and Canada, each seeking to increase their level of participation within the global medicinal cannabis industry.
Price Action 
Instadose Pharma&rsquo;s shares closed Tuesday market session flat at $2.75 per share. 
Photo: Courtesy of <a href="https://unsplash.com/@diyahna22?utm_source=unsplash&amp;utm_medium=referral&amp;utm_content=creditCopyText">Diyahna Lewis</a> on <a href="https://unsplash.com/s/photos/marijuana?utm_source=unsplash&amp;utm_medium=referral&amp;utm_content=creditCopyText">Unsplash</a>

Direxion, the second-largest issuer of inverse and leveraged ETFs, will shutter three of its non-leveraged products that failed to attract adequate assets under management totals. Prior to the Direxion announcement, nearly 100 exchange-traded products had been closed this year, an industry record.

Direxion will close the Direxion Large Cap Insider Sentiment Shares (NYSE: <a class="ticker" href="/stock/insd#NYSE">INSD</a>), Direxion S&amp;P 1500 DRRC Index Volatility Response Shares (NYSE: <a class="ticker" href="/stock/vspr#NYSE">VSPR</a>) and Direxion S&amp;P Latin America 40 DRRC Index Volatility Response Shares (NYSE: <a class="ticker" href="/stock/vlat#NYSE">VLAT</a>), <a href="http://www.etftrends.com/2012/12/three-direxion-etfs-to-close/">according to ETF Trends</a>. Those ETFs will liquidate next month.

In September, Direxion closed nine of its leveraged ETFs inlcuding the Direxion Daily Basic Materials Bear 3X Shares, Direxion Daily BRIC Bull 3X Shares, Direxion Daily Latin America Bear 3X Shares <a href="Direxion%20Daily%20Latin%20America%20Bear%203X%20Shares%20and%20the">Direxion Daily Retail Bull 3X Shares.

Direxion's other non-leveraged ETFs include the Direxion All Cap Insider Sentiment Shares (NYSE: </a><a class="ticker" href="/stock/know#NYSE">KNOW</a>) and the Direxion NASDAQ-100 Equal Weighted Index Shares (NYSE: <a class="ticker" href="/stock/qqqe#NYSE">QQQE</a>).

For more on ETFs, click <a href="http://www.benzinga.com/etfs">here</a>.

Insiders may sell shares for any number of reasons, but there is really only one reason insiders buy shares of a company -- they believe the stock price will move higher and they want to profit from it. Pullbacks and sell-offs provide a perfect opportunity for investors who have faith in a company to snap up shares. Here are some stocks that have seen insider buying recently.

Cracker Barrel Old Country Store (NASDAQ: <a class="ticker" href="/stock/cbrl#NASDAQ">CBRL</a>): This retailer and restaurateur had more than 287,000 shares, worth over $14.9 million, purchased by a Sardar Biglari, a so-called beneficial owner, in the last 10 days in January. Cracker Barrel has a market cap of $1.2 billion, a dividend yield of 1.9% and a return on equity of 32.9%. The share price is up more than 26% in the past three months and in the region of the 52-week high. Over that time, the stock has outperformed the Nasdaq and competitors such as Denny's (NASDAQ: <a class="ticker" href="/stock/denn#NASDAQ">DENN</a>) and DineEquity (NYSE: <a class="ticker" href="/stock/din#NYSE">DIN</a>).

See also: <a href="http://www.benzinga.com/news/11/12/2196590/sardar-biglari-letter-to-shareholders-of-cracker-barrel-old-country-store"> Sardar Biglari Letter to Shareholders of Cracker Barrel Old Country Store</a>.

Dominion Resources (NYSE: <a class="ticker" href="/stock/d#NYSE">D</a>):The CEO, CFO and two directors scooped up more than 17,000 shares, worth more than $881,000, at the end of January. This diversified energy company has a market cap of $28.7 billion and a dividend yield of 4.2%. The stock has pulled back about 5% in the past month, falling below the 50-day moving average, but not the 200-day moving average. Over the past six months, the stock has underperformed competitors American Electric Power (NYSE: <a class="ticker" href="/stock/aep#NYSE">AEP</a>) and NiSource (NYSE: <a class="ticker" href="/stock/ni#NYSE">NI</a>), as well as the Dow.

Hess Corp. (NYSE: <a class="ticker" href="/stock/hes#NYSE">HES</a>): The chairman of the board recently purchased more than 91,000 shares. That was worth almost $5 million. This New York-based integrated energy company has a market cap of $19.3 million and a P/E ratio this is a little less than the industry average. Its dividend yield is 0.7%. Shares pulled back slightly in the past week and are down more than 33% from a year ago. The stock has underperformed larger competitors BP (NYSE: <a class="ticker" href="/stock/bp#NYSE">BP</a>) and Exxon Mobil (NYSE: <a class="ticker" href="/stock/xom#NYSE">XOM</a>), as well as the broader markets, over the past six months.

Icahn Enterprises (NYSE: <a class="ticker" href="/stock/iep#NYSE">IEP</a>): Carl Icahn, the chairman of the board, bought up more than 12.9 million shares in January. That was worth more than $475 million. The market cap of his diversified company is $3.2 billion and its dividend yield is 1.0%. The P/E ratio is 6.3 and the company has a return on equity of 15.3%. Shares have traded mostly between $36 and $39 since November and are below where they were a year ago. Over the past six months, the stock has underperformed the broader markets and Warren Buffet's Berkshire Hathaway (NYSE: BRK-A).

Community Bank System (NYSE: <a class="ticker" href="/stock/cbu#NYSE">CBU</a>): Some 11,000 shares, worth more than $264,000, were purchased last week by seven of this regional bank's directors. The upstate New York-based bank holding company has a market cap of $1.1 billion and posted record Q4 EPS. Its long-term EPS growth forecast is 9.9% and the dividend yield is 3.7%. The share price pulled back about 3% recently from a 52-week high. Over the past six months, the stock outperformed competitors M&amp;T Bank (NYSE: <a class="ticker" href="/stock/mtb#NYSE">MTB</a>) and State Street (NYSE: <a class="ticker" href="/stock/stt#NYSE">STT</a>), as well as the broader markets.

See also: <a href="http://www.benzinga.com/news/12/01/2276649/community-bank-system-announces-agreement-to-acquire-19-branches-and-955-million-">Community Bank System Announces Agreement to Acquire 19 Branches and $955 Million in Deposits</a>.

Colfax (NYSE: <a class="ticker" href="/stock/cfx#NYSE">CFX</a>): One director recently purchased more than 2.1 million shares, worth about $50 million. The same director also bought shares in October. The Maryland-based company makes industrial products and has a market cap of $1.3 billion. The long-term EPS growth forecast is 19.6%. The P/E ratio is hefty but expected to fall. The share price has pulled back a bit in the past week and is down more than 9% from a recent 52-week high. The stock has outperformed the broader markets and competitor Robbins &amp; Myers (NYSE: <a class="ticker" href="/stock/rbn#NYSE">RBN</a>) over the past six months.

See also: <a href="http://www.benzinga.com/general/psychology/12/01/2297379/insider-sentiment-is-neutral-to-bearish-in-january-2012">Insider Sentiment Is Neutral to Bearish in January 2012</a>.

<div id="action-items">ACTION ITEMS:

Bullish: Investors interested in exchange traded funds focused on insider sentiment might want to consider the following trades:

<ul><li>Guggenheim Insider Sentiment (NYSE: <a class="ticker" href="/stock/nfo#NYSE">NFO</a>) is about 31% higher than the 52-week low.</li>
<li>Direxion All Cap Insider Sentiment Shares (NYSE: <a class="ticker" href="/stock/know#NYSE">KNOW</a>) is more than 19% higher than the 52-week low.</li>
<li>Direxion Large Cap Insider Sentiment Shares (NYSE: <a class="ticker" href="/stock/insd#NYSE">INSD</a>) is almost 12% higher than the 52-week low.</li>
</ul>Bearish: Traders may prefer to consider these alternative positions to some of the stocks listed above:

<ul><li>Papa John's International (NASDAQ: <a class="ticker" href="/stock/pzza#NASDAQ">PZZA</a>) is up about 47% from the 52-week low.</li>
<li>Marathon Oil (NYSE: <a class="ticker" href="/stock/mro#NYSE">MRO</a>) is up about 66% from the 52-week low.</li>
<li>Danaher (NYSE: <a class="ticker" href="/stock/dhr#NYSE">DHR</a>) is up more than 34% from the 52-week low.</li>
<li>Republic Bancorp (NYSE: <a class="ticker" href="/stock/rbcaa#NYSE">RBCAA</a>) is up more than 66% from the 52-week low.</li>
</ul>Neither Benzinga nor its staff recommend that you buy, sell, or hold any security. We do not offer investment advice, personalized or otherwise. Benzinga recommends that you conduct your own due diligence and consult a certified financial professional for personalized advice about your financial situation.</div>

Comments

Instadose Pharma

Instadose Pharma (INSD) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga